FDA approves Gilead's Vemlidy drug for children with hepatitis B

 Gilead Sciences Inc . (NASDAQ: NASDAQ:GILD) announced the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir alafenamide) 25 mg tablets for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.